In-hospital costs of coronary stent implantation with and without eptifibatide (the ESPRIT Trial). Enhanced Suppression of the Platelet IIb/IIIa Receptor with Integrilin.
Cohen
David J
DJ
Cardiovascular Division, Beth Israel Deaconess Medical Center, Boston, Massachusetts 02215, USA. djc@hsph.harvard.edu
O'Shea
J Conor
JC
Pacchiana
Cindy M
CM
Levine
Glenn
G
Sarembock
Ian
I
Slater
James
J
Conn
Eric
E
Smith
Jack
J
Tcheng
James E
JE
D015906:Angioplasty, Balloon, Coronary / Q000191:economics*; D003324:Coronary Artery Disease / Q000628:therapy*; D018592:Cross-Over Studies; D004311:Double-Blind Method; D000077542:Eptifibatide; D005260:Female; D017721:Hospital Costs; D006801:Humans; D007902:Length of Stay; D008297:Male; D008875:Middle Aged; D010455:Peptides / Q000191:economics / Q000627:therapeutic use*; D010975:Platelet Aggregation Inhibitors / Q000191:economics / Q000627:therapeutic use*; D019039:Platelet Glycoprotein GPIIb-IIIa Complex / Q000037:antagonists & inhibitors*; D016032:Randomized Controlled Trials as Topic; D015607:Stents; D014481:United States
D010455:Peptides; D010975:Platelet Aggregation Inhibitors; D019039:Platelet Glycoprotein GPIIb-IIIa Complex; D000077542:Eptifibatide